ImmunoGen, Inc. (NASDAQ:IMGN) belonging to the Medical sector which declined -1.87% and closed its last trading session at $2.63.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 10/28/2016. Currently, the stock has a 1 Year Price Target of $5.71.
The consensus recommendation, according to Zacks Investment research, is 2.61. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.61 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.66 and 2.48 respectively.
ImmunoGen, Inc. on 6/30/2016 reported its EPS as $-0.51 with the analysts projecting the EPS of the stock as $-0.39. The company beat the analyst EPS Estimate with the difference of $-0.12. This shows a surprise factor of -30.8%.
Many analysts have provided their estimated foresights on ImmunoGen, Inc. Earnings, with 7 analysts believing the company would generate an Average Estimate of $-0.38. Whereas they predicted High and Low Earnings Estimate as $-0.34 and $-0.44 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.39.
Analysts are also projecting an Average Revenue Estimate for ImmunoGen, Inc. as $21.12 Million in the Current Quarter. This estimate is provided by 4 analysts. The High Revenue estimate is predicted as 22.06 Million, while the Low Revenue Estimate prediction stands at 19.6 Million. The company’s last year sales total was 14.85 Million.
The Company got Downgrade by RBC Capital Mkts on 29-Apr-16 from Outperform to Sector Perform.
Insider Trades for ImmunoGen, Inc. show that the latest trade was made on 1 Jun 2016 where Junius (Daniel M), the Director completed a transaction type “Buy” in which 27085 shares were traded at a price of $3.19.
15 Insider Sales transactions were made totaling 116544 shares traded.
7 analysts projected Price Targets for ImmunoGen, Inc. The analysts believe that the company stock price could grow as high as $8.5. The Low Price target projection by analysts is $2.5 and the Mean Price Target is $5.71.
ImmunoGen, Inc. (NASDAQ:IMGN) has the market capitalization of $228.97 Million. The company rocked its 52-Week High of $14.22 on Nov 25, 2015 and touched its 52-Week Low of $2.53 on Aug 4, 2016. The stock has Return on Assets (ROA) of -55.3 percent. Return on Equity (ROE) stands at 450.7% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -80.62 Percent. The company has Beta Value of 2.04 and ATR value of 0.14. The Weekly and Monthly Volatility stands at 4.47% and 5.10%.
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.